Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors

9 Sept 2011

Abstract excerpt

In an effort to develop strategies that improve the efficacy of existing anticancer agents, we have conducted a siRNA-based RNAi screen to identify genes that, when targeted by siRNA, improve the activity of the topoisomerase I (Top1) poison camptothecin (CPT). Screening was conducted using a set of siRNAs corresponding to over 400 apoptosisrelated genes in MDA-MB-231 breast cancer cells. During the course of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer therapeutics and mechanisms
Share to Cell death mechanisms and regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21834757
DOI: 10.2174/156800911797264734

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase InhibitorsPMID 21834757Read ↗

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cellsSemantic proximity Read ↗

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoverySemantic proximity Read ↗

Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic AnalysesSemantic proximity Read ↗

Pharmacogenomic Identification of Targets for Adjuvant Therapy with the Topoisomerase Poison CamptothecinSemantic proximity Read ↗

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.Semantic proximity Read ↗

Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protectiveSemantic proximity Read ↗

Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.Semantic proximity Read ↗

Differential Targeting of Human Topoisomerase II Isoforms with Small MoleculesSemantic proximity Read ↗

Novel camptothecin derivatives as topoisomerase I inhibitorsSemantic proximity Read ↗

Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read ↗

YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIα at the ATP-Binding SiteSemantic proximity Read ↗

A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor ActivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.